STOCK TITAN

Tetra Bio-Pharma Signs License Agreement with Thorne for a Prebiotic Dietary Supplement

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Tetra Bio-Pharma has entered a licensing agreement with Thorne Health Tech for the commercialization of a patented prebiotic dietary supplement in the U.S. market. This partnership includes royalties on sales and milestone payments. The U.S. prebiotics market is projected to surpass USD 9.5 billion by 2027, growing at a CAGR of 9.6% from 2021. Tetra's CEO expressed enthusiasm about collaborating with Thorne, known for its evidence-based supplements, to bring their product to consumers.

Positive
  • Signed licensing agreement with Thorne Health Tech for a prebiotic dietary supplement.
  • Projected growth of U.S. prebiotics market could enhance revenue potential for Tetra.
  • Includes potential royalties on sales and milestone payments.
Negative
  • None.

OTTAWA, ON, Feb. 22, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, today announced it has signed a Licensing Agreement with Thorne Health Tech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellbeing, for the commercialization of its patent protected prebiotic dietary supplement in the U.S. market. The Agreement will include royalty on sales and milestone payments. The prebiotics market size in the United States is expected to exceed USD 9.5bn by 2027 with a strong CAGR of 9.6% in 2021⃰. 

"Thorne has an established reputation as a world leader in the sales and distribution of evidence-based supplements for consumer self-care and physician-directed therapies and Tetra is excited to partner with them to bring this product to market," said Guy Chamberland, CEO of Tetra Bio-Pharma.

= Global Marketing Insights (GMI) Insights to Innovation April 14, 2021

About Thorne HealthTech
Thorne HealthTech is a leader in developing innovative solutions for a personalized approach to health and wellbeing. Thorne HealthTech is a science-driven wellness company that is utilizing testing and data to create improved product efficacy and deliver personalized solutions to consumers, health professionals, and corporations. Thorne HealthTech's unique, vertically integrated brands, Thorne and Onegevity, provide insights and personalized data, products, and services that help individuals take a proactive and actionable approach to improve and maintain their health over a lifetime.

About Tetra Bio-Pharma
Tetra Bio-Pharma is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra's evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what they do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians, and insurance companies.

For more information visit: www.tetrabiopharma.com

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of this product  or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/tetra-bio-pharma-signs-license-agreement-with-thorne-for-a-prebiotic-dietary-supplement-301486986.html

SOURCE Tetra Bio-Pharma Inc.

FAQ

What is Tetra Bio-Pharma's latest agreement with Thorne Health Tech?

Tetra Bio-Pharma signed a licensing agreement with Thorne Health Tech for the commercialization of a patented prebiotic dietary supplement.

What does the licensing agreement between Tetra Bio-Pharma and Thorne include?

The agreement includes royalties on sales and milestone payments.

How large is the U.S. prebiotics market expected to grow?

The U.S. prebiotics market is projected to exceed USD 9.5 billion by 2027, with a CAGR of 9.6% from 2021.

What is the significance of the agreement for Tetra Bio-Pharma?

The agreement positions Tetra to potentially benefit from a growing market, enhancing revenue opportunities.

Which stock symbols are associated with Tetra Bio-Pharma and Thorne Health Tech?

Tetra Bio-Pharma is traded under the symbols TBPMF and TBP, while Thorne Health Tech trades as THRN.

Tetra Bio-Pharma Inc.

:TBPMF

TBPMF Rankings

TBPMF Latest News

TBPMF Stock Data

1.75M
418.75M
0.99%
Biotechnology
Healthcare
Link
Canada
Orléans